Trimodality therapy for bladder conservation in treatment of invasive bladder cancer

Timur Mitin, William U. Shipley, Jason A. Efstathiou, Niall M. Heney, Donald S. Kaufman, Richard J. Lee, Anthony L. Zietman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

During the past 25 years, prospective clinical trials have established that bladder preservation therapy for select patients with muscle-invasive bladder cancer is a safe and effective alternative to an immediate cystectomy. Cisplatin-based chemoradiation is the most well-studied and accepted component of trimodality therapy; however, other systemic agents have recently been shown effective in combination with radiation therapy, increasing the range of options to allow for better personalization of care. In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined.

Original languageEnglish (US)
Pages (from-to)109-115
Number of pages7
JournalCurrent Urology Reports
Volume14
Issue number2
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Cystectomy
Cisplatin
Radiotherapy
Therapeutics
Clinical Trials
Muscles

Keywords

  • Bladder cancer
  • Bladder preservation
  • Cystectomy
  • Muscle invasive
  • Radiation therapy
  • Trimodality therapy

ASJC Scopus subject areas

  • Urology

Cite this

Mitin, T., Shipley, W. U., Efstathiou, J. A., Heney, N. M., Kaufman, D. S., Lee, R. J., & Zietman, A. L. (2013). Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Current Urology Reports, 14(2), 109-115. https://doi.org/10.1007/s11934-012-0301-x

Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. / Mitin, Timur; Shipley, William U.; Efstathiou, Jason A.; Heney, Niall M.; Kaufman, Donald S.; Lee, Richard J.; Zietman, Anthony L.

In: Current Urology Reports, Vol. 14, No. 2, 04.2013, p. 109-115.

Research output: Contribution to journalArticle

Mitin, T, Shipley, WU, Efstathiou, JA, Heney, NM, Kaufman, DS, Lee, RJ & Zietman, AL 2013, 'Trimodality therapy for bladder conservation in treatment of invasive bladder cancer', Current Urology Reports, vol. 14, no. 2, pp. 109-115. https://doi.org/10.1007/s11934-012-0301-x
Mitin, Timur ; Shipley, William U. ; Efstathiou, Jason A. ; Heney, Niall M. ; Kaufman, Donald S. ; Lee, Richard J. ; Zietman, Anthony L. / Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. In: Current Urology Reports. 2013 ; Vol. 14, No. 2. pp. 109-115.
@article{74273b4adf004a29a4c2d11df752c05d,
title = "Trimodality therapy for bladder conservation in treatment of invasive bladder cancer",
abstract = "During the past 25 years, prospective clinical trials have established that bladder preservation therapy for select patients with muscle-invasive bladder cancer is a safe and effective alternative to an immediate cystectomy. Cisplatin-based chemoradiation is the most well-studied and accepted component of trimodality therapy; however, other systemic agents have recently been shown effective in combination with radiation therapy, increasing the range of options to allow for better personalization of care. In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined.",
keywords = "Bladder cancer, Bladder preservation, Cystectomy, Muscle invasive, Radiation therapy, Trimodality therapy",
author = "Timur Mitin and Shipley, {William U.} and Efstathiou, {Jason A.} and Heney, {Niall M.} and Kaufman, {Donald S.} and Lee, {Richard J.} and Zietman, {Anthony L.}",
year = "2013",
month = "4",
doi = "10.1007/s11934-012-0301-x",
language = "English (US)",
volume = "14",
pages = "109--115",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Trimodality therapy for bladder conservation in treatment of invasive bladder cancer

AU - Mitin, Timur

AU - Shipley, William U.

AU - Efstathiou, Jason A.

AU - Heney, Niall M.

AU - Kaufman, Donald S.

AU - Lee, Richard J.

AU - Zietman, Anthony L.

PY - 2013/4

Y1 - 2013/4

N2 - During the past 25 years, prospective clinical trials have established that bladder preservation therapy for select patients with muscle-invasive bladder cancer is a safe and effective alternative to an immediate cystectomy. Cisplatin-based chemoradiation is the most well-studied and accepted component of trimodality therapy; however, other systemic agents have recently been shown effective in combination with radiation therapy, increasing the range of options to allow for better personalization of care. In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined.

AB - During the past 25 years, prospective clinical trials have established that bladder preservation therapy for select patients with muscle-invasive bladder cancer is a safe and effective alternative to an immediate cystectomy. Cisplatin-based chemoradiation is the most well-studied and accepted component of trimodality therapy; however, other systemic agents have recently been shown effective in combination with radiation therapy, increasing the range of options to allow for better personalization of care. In this review, the most recent advances in the field of bladder-preserving trimodality therapy are presented, and future directions for improving the outcomes are outlined.

KW - Bladder cancer

KW - Bladder preservation

KW - Cystectomy

KW - Muscle invasive

KW - Radiation therapy

KW - Trimodality therapy

UR - http://www.scopus.com/inward/record.url?scp=84879603299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879603299&partnerID=8YFLogxK

U2 - 10.1007/s11934-012-0301-x

DO - 10.1007/s11934-012-0301-x

M3 - Article

VL - 14

SP - 109

EP - 115

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 2

ER -